This Prospectus
Supplement No. 1 supplements the prospectus dated June 17, 2016 relating to the resale by the Selling Shareholders of up to 982,472
shares of our Common Stock, par value $0.001 per share (the “Common Stock”). Of the Common Stock offered herein, 804,139
shares are issuable upon the exercise of warrants held by placement agents that were issued in connection with our March 2014 Private
Placement, 45,000 shares were issued to Merriman Capital, Inc. under an Advisory Agreement dated February 23, 2015 and 133,333
shares were issued to Mr. Shadron Stastney under a Separation Agreement dated September 20, 2013.
This Prospectus
Supplement No. 1 incorporates into our prospectus the information contained in our attached Current Report on Form 8-K, which was
filed with the Securities and Exchange Commission on June 27, 2016.
You should read
this Prospectus Supplement No. 1 in conjunction with the prospectus, including any supplements and amendments thereto.
This Prospectus
Supplement No. 1 is qualified by reference to the prospectus except to the extent that the information in this Prospectus Supplement
No. 1 supersedes the information contained in the prospectus. This Prospectus Supplement No. 1 is not complete without, and may
not be delivered or utilized except in connection with, the prospectus, including any supplements and amendments thereto.
Our Common
Stock is traded on the OTCQB under the symbol “OPRX.” On June 27, 2016, the last reported sale price of our Common
Stock was $1.14 per share.
Check the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following provisions:
The information provided in Item 5.02 concerning the entry into a material
definitive agreement is incorporated by reference in this Item 1.01.
Effective June 22, 2016, we have appointed Mr. Brian Dillon as our Senior
Vice President of Product and Strategy.
With over 35 years’ experience with Software Systems and Services
in the Insurance, Pharmaceutical, Pharmacy and Healthcare sectors, Mr. Dillon has been the driving force and founder of a series
of successful start-up companies in Canada (QuadROM) and the US (Kelly Waldron Technology Solutions) with successful transitions
in all cases. As a result of those transitions he has had the pleasure of working within Fortune 30 companies in senior management
roles both domestically (McKesson) and internationally (Cegedim). The mission of each company had focused on delivering advanced
sales & marketing systems, technology platforms and related services to the sectors stated above. More recently, 2006 to present,
Mr. Dillon has been involved in the Health Information Technology sector as a consultant to a variety of companies with mandates
including an interim role of CEO for an Electronic Health Records (EHR) company, a senior business development strategist for
a publicly traded eRx systems provider in Canada, a business development specialist for a unique data mining company, product/channel
strategist for a large CoPay company as well as to a select number of strategic clients within the HiTech sector.
Aside from that provided above, Mr. Dillon does not hold and has not held
over the past five years any other directorships in any company with a class of securities registered pursuant to Section 12 of
the Exchange Act or subject to the requirements of Section 15(d) of the Exchange Act or any company registered as an investment
company under the Investment Company Act of 1940.
There are no family relationships between Mr. Dillon and any of our directors
or executive officers.
Aside from the following, Mr. Dillon has not had any material direct or
indirect interest in any of our transactions or proposed transactions over the last two years.
On June 22, 2016, Mr. Dillon and our company entered into an agreement
to consult with our company as our Senior Vice President of Product and Strategy. Pursuant to the agreement, Mr. Dillon will receive
an annual base salary of $185,000 and he will be eligible for a bonus of up to 30% of his base salary based on our executive bonus
plan. The bonus is payable in shares of our common stock or a combination of 50% cash and 50% equity, as requested by Mr. Dillon.
In addition, we also agreed to recommend to the Board of Directors that
our company grant to Mr. Dillon an option under our 2013 Incentive Plan to purchase 100,000 shares of our common stock with an
exercise price at fair market value per share on the date of grant. In addition, we agreed to recommend to the Board of Directors
that the company grant to Mr. Dillon an option under our 2013 Incentive Plan to purchase 300,000 shares of our common stock with
an exercise price at fair market value per share on the date of grant should we determine, in our sole discretion, that Mr. Dillon
is responsible for achieving $2 million in new business from additional products or product extensions.
The options will be subject to vesting and other terms as set forth in
the 2013 Incentive Plan, Stock Option Grant Notice and Stock Option Agreement.
The agreement further provides that if Mr. Dillon’s consultancy with
us is involuntarily terminated without cause, Mr. Dillon will be entitled to receive a severance payment of up to six months of
his applicable base pay, provided that he has served for a period of six months beforehand.
The agreement contains a Business Protection Agreement that contains restrictive
covenants that include a non-compete both during the consultancy and for a period of one year thereafter, and an inventions assignment
clause both during the consultancy and for a period of six months thereafter. The agreement also contains a confidentiality provision.
The foregoing description of the agreement is qualified in its entirety
by reference to the full text of the agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated
by reference herein.
On June 27, 2016, we entered into an updated employment agreement with
Mr. Doug Baker to continue serving as our Chief Financial Officer. Under the agreement, we agreed to compensate Mr. Baker $180,000
annually and he will be eligible for a bonus of up to 30% of his base salary based on our executive bonus plan. The bonus is payable
in shares of our common stock or a combination of 50% cash and 50% equity, as requested by Mr. Baker. Mr. Baker is also eligible
for employee benefits, including our 401(k) plan, medical and dental insurance and short and long term disability. The agreement
further provides that if Mr. Baker’s employment with us is involuntarily terminated without cause, Mr. Baker will be entitled
to receive a severance payment of up to six months of his applicable base pay.
The agreement contains a Business Protection Agreement that contains restrictive
covenants that include a non-compete both during the employment and for a period of one year thereafter, and an inventions assignment
clause both during the employment and for a period of six months thereafter. The agreement also contains a confidentiality provision.
A copy of the updated employment agreement is attached hereto as Exhibit
10.2, and is incorporated herein by reference. The foregoing description of the employment agreement is qualified in its entirety
by reference to the full text thereto.
On June 27, 2016, we entered into an updated employment agreement with
Mr. Terry Hamilton to continue serving as our Senior Vice President of Sales. Under the agreement, we agreed to compensate Mr.
Hamilton $181,650 annually and he will be eligible for a bonus of up to 40% of his base salary based on our executive bonus plan.
The bonus is payable in shares of our common stock or a combination of 50% cash and 50% equity, as requested by Mr. Hamilton.
Mr. Hamilton is also eligible for employee benefits, including our 401(k) plan, medical and dental insurance and short and long
term disability. The agreement further provides that if Mr. Hamilton’s employment with us is involuntarily terminated without
cause, Mr. Hamilton will be entitled to receive a severance payment of up to twelve months of his applicable base pay.
The agreement contains a Business Protection Agreement that contains restrictive
covenants that include a non-compete both during the employment and for a period of one year thereafter, and an inventions assignment
clause both during the employment and for a period of six months thereafter. The agreement also contains a confidentiality provision.
A copy of the updated employment agreement is attached hereto as Exhibit
10.3, and is incorporated herein by reference. The foregoing description of the employment agreement is qualified in its entirety
by reference to the full text thereto.
On June 22, 2016, we issued a press release concerning the appointment
of Mr. Brian Dillon to the new position of SVP of Product and Strategy. A copy of the press release is attached as Exhibit 99.1
to this Current Report on Form 8-K.
The information in Item 7.01 of this Current Report on Form 8-K (including
Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange
Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing
under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
SIGNATURES
Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
OptimizeRx Corporation
|
|
|
|
|
|
/s/ Doug Baker
|
|
|
Doug Baker
|
|
|
Chief Financial Officer
|
|
Date: June 27, 2016
Exhibit 10.1
Agreement
This agreement made and entered into this June 22, 2016, by and between
OptimizeRx Corporation, a Nevada Company, hereinafter referred to as “Employer” and Brian Dillon, hereinafter referred
to as the “Consultant”.
The Employer is engaged in the business of Pharmaceutical and healthcare
promotion to physicians and consumers through their electronic platforms and other means and desires Brian Dillon to serve as the
Senior Vice-President Product & Strategy for the company.
Base Compensation
. Your annual consulting fee is $185,000 at the
rate of $7,708.33 per semi-monthly pay period, representing payment for all hours worked (“Base Compensation”). Your
Base Compensation is payable in accordance with the Company’s regular practices. Your pay for the first pay period of your
consulting will be prorated based on the number of days you work in that pay period.
Bonus.
In addition to your Base Compensation, you will be eligible
to participate in the Company’s executive bonus plan, subject to its terms and conditions, with the potential to earn a bonus
of 30 % of your Base Compensation. Brian has the option to take the bonus in equity or to have a split 50/50 arrangement with 50%
in cash and 50 % in equity. The option as to which is at the discretion of Brian Dillon.
Job Responsibilities
. As Sr. Vice President of Product and Strategy
reporting to the CEO, you are an essential member and part of our corporate management. You shall use your best efforts and devote
your full time and attention to the business of the Company on a full time basis and shall at all times faithfully and industriously
and to the best of your ability, experience and talent, perform all of the duties that may be required of you pursuant to the terms
hereof. During the term hereof you shall not engage in any other employment or consulting activities without the express written
consent of the Company other than civic, charitable and/or religious activities, directing your own passive investments and/or
serving on boards of directors of other entities so long as such activities do not interfere or conflict with your duties hereunder
as reasonably determined by the Company.
Equity.
We will recommend to the Board of Directors that the Company
grant you an option to purchase up to one hundred thousand (100,000) shares of the Company’s Common Stock at an exercise
price equal to the fair market value of such shares on the date of the grant (“New Hire Share Options”). The New Hire
Share Options will be granted to you pursuant to the terms of the 2013 Incentive Plan, a Stock Option Grant Notice and Stock Option
Agreement, and such documents will contain applicable vesting terms and otherwise govern the terms and conditions of the equity
grant.
In addition to the New Hire Share Options, we will also recommend to the
Board of Directors that the Company grant you an additional option to purchase up to three-hundred thousand (300,000) shares of
the Company’s Common Stock at an exercise price equal to the fair market value of such shares on the date of the grant (“New
Business Share Options”) should the Company determine in its sole discretion that you have been responsible for achieving
two million dollars ($2M) in new business from additional products or product extensions. The New Business Share Options, if granted,
will be granted to you pursuant to the terms of the 2013 Incentive Plan, a Stock Option Grant Notice and Stock Option Agreement,
and such documents will contain applicable vesting terms and otherwise govern the terms and conditions of the equity grant.
Expense Reimbursement
. We will reimburse you for all approved business
travel costs incurred by you pursuant to the terms of the Company travel policy.
At-Will Agreement.
Please note that you are not being offered
employment, nor consulting for a definite period of time, and that either you or the Company may terminate your consulting agreement
at any time for any reason, with or without cause or notice, except as prohibited by law. Nothing in this offer to you should be
interpreted as creating anything other than an at-will consulting relationship. You also have the right to terminate your consulting
with the company at any time for any reason on thirty days’ prior written notice.
Business Protection Agreement.
The Company considers the protection
of its confidential information, proprietary materials and goodwill to be extremely important. Accordingly, as a condition of your
agreement with the Company, you will be required to execute and return to the Company the enclosed Business Protection Agreement
on or before your first day of consulting.
Conflicts of Interest and Gifts.
You will promptly
disclose
all current and potential interests, direct or indirect, in any entity dealing with the Company which may affect actions and decisions
made by you as a representative of the Company, and fully disclose any gift which raises any reasonable possibility of conflict
of interest.
Compliance
. You will comply with all applicable laws and Company
policies in performing your duties hereunder including federal and state securities laws.
Severance Pay.
If the Consultant’s agreement is terminated
at any time, after the completion of six months of service, by the Company without cause, which termination shall be effective
immediately upon the date of delivery of written notice to Consultant (or at such later date as otherwise specified in such
notice), the Company shall continue to pay to the Consultant, as severance pay, the monthly portion of the Consultant’s annual
base rate for a period of six (6) months following such termination, subject to the Consultant’s compliance with the terms
and conditions of this Agreement and the Business Protection Agreement.
Except as set forth herein, or as set forth in your option agreements, or
as may be required by applicable law, you have no right to any specific compensation or benefits, and the Company shall have no
obligations to pay any salary, bonus, severance payment, accrued vacation or other amounts in connection with any termination of
your consulting or attributable to the period after termination.
Required Documentation.
Your consulting for the Company is also subject
to you providing the Company with proof of your legal right to work in the United States by providing the Company with acceptable
documentation.
Certifications.
As a condition of your consulting, you certify
to the Company that you are free to enter into and fully perform the duties of your position, and that you are not subject to any
employment, confidentiality, non-competition or other agreement that would restrict your performance for the Company. If you are
subject to any such agreement, please forward it to the Company as soon as possible.
Additionally, as a condition of your consulting, you certify that you will
not disclose to or use for the benefit of the Company any trade secret or confidential or proprietary information of any previous
employer. You further affirm that you have not divulged or used any such information for the benefit of the Company, and that you
have not and will not misappropriate any such information from any former employer.
Entire Agreement
. This offer letter and your signed Business Protection
Agreement, states the terms of your consulting agreement and supersedes and cancels any prior oral or written representations,
offers or promises made by the Company and any understandings or agreements, whether written or oral, between the Company and you.
|
Accepted by Employer:
|
|
Accepted by Employee:
|
|
|
|
|
|
/s/ William J. Febbo
|
|
/s/ Brian Dillon
|
|
William J. Febbo (Date)
|
|
Brian Dillon (Date)
|
Exhibit 10.2
Employment
Agreement
This
updated agreement made and entered into this June 27, 2016, by and between OptimizeRx Corporation, a Nevada Company, hereinafter
referred to as “Employer” and Douglas P. Baker, hereinafter referred to as the “Employee”.
The
Employer is engaged in the business of Pharmaceutical and healthcare promotion to physicians and consumers through their electronic
platforms and other means and desires Douglas P. Baker to serve as the Chief Financial Officer for the company.
Base
Compensation
. Your annual base salary, commencing June 1, 2016, is $180,000, payable at a rate of $7,500.00 per semi-monthly
pay period, representing payment for all hours worked (“Base Compensation”). Your Base Compensation is payable in
accordance with the Company’s regular practices.
Bonus.
In
addition to your Base Compensation, you will be eligible to participate in the Company’s executive bonus plan, subject to
its terms and conditions, with an annual target bonus of 30 % of your Base Compensation. Subject to board approval and registration
of the plans and related legal compliance, you will have the option to take the bonus in equity or in a split 50/50 arrangement
with 50% in cash and 50 % in equity. The option to take all, or a portion, of your bonus in equity is at your discretion.
Employee
Benefits.
In addition to your compensation, you will have the opportunity to participate in various Company benefit programs
generally offered to employees, pursuant to the terms and conditions of such programs, including applicable waiting periods prior
to eligibility. Currently, we offer employees a 401(k) plan, group medical and dental insurance and short and long term disability
benefits. Please note that the Company reserves the right to change or discontinue any of our benefits, plans, providers, and
policies, at any time.
Job
Responsibilities
. As Chief Financial Officer, your responsibilities include oversite and management of all financial and
human resources activities, as well as other duties from time-to-time assigned by the CEO. You shall use your best efforts and
devote your full time and attention to the business of the Company on a full time basis and shall at all times faithfully and
industriously and to the best of your ability, experience and talent, perform all of the duties that may be required of you pursuant
to the terms hereof. During the term hereof you shall not engage in any other new employment or consulting activities without
the express written consent of the Company other than civic, charitable and/or religious activities, directing your own passive
investments and/or serving on boards of directors of other entities so long as such activities do not interfere or conflict with
your duties hereunder as reasonably determined by the Company.
Expense
Reimbursement
. The Company will reimburse you for all approved business travel costs incurred by you pursuant to the terms
of the Company travel policy.
At-Will
Employment.
Please note that you are not being offered employment for a definite period of time, and that the Company may
terminate your employment at any time for any reason, with or without cause or notice, except as prohibited by law. Nothing in
this offer to you should be interpreted as creating anything other than an at-will employment relationship. You also have the
right terminate your employment with the company at any time for any reason on thirty days’ prior written notice.
Business
Protection Agreement.
The Company considers the protection of its confidential information, proprietary materials and goodwill
to be extremely important. Accordingly, as a condition of your continued employment with the Company and the increase in compensation
reflected herein, you will be required to execute and return to the Company the enclosed Business Protection Agreement.
Conflicts
of Interest and Gifts. You will promptly
disclose all current and potential interests, direct or indirect, in any entity dealing
with the Company which may affect actions and decisions made by you as a representative of the Company, and fully disclose any
gift which raises any reasonable possibility of conflict of interest.
Compliance
.
Unless otherwise directed by the CEO or Board of Directors, you will to the best of your knowledge comply with all applicable
laws and Company policies in performing your duties hereunder including federal and state securities laws.
Severance
Pay
. If your employment agreement is terminated at any time by the Company without cause, which termination shall be effective
immediately upon the date of delivery of written notice to you (or at such later date as otherwise specified in such notice),
the Company shall continue to pay you, as severance pay, the monthly portion of your Base Compensation for a period of six (6)
months following such termination, subject to your continued compliance with the terms and conditions of this Agreement and the
Business Protection Agreement.
Except
as set forth herein, or as set forth in your option agreements, or as may be required by applicable law, you have no right to
any specific compensation or benefits, and the Company shall have no obligations to pay any salary, bonus, severance payment,
accrued vacation or other amounts in connection with any termination of your employment or attributable to the period after termination.
409A
.
To the extent that any provision of this letter agreement is ambiguous as to its exemption or compliance with Code Section 409A,
the provision will be read in such a manner so that all payments hereunder are exempt from Code Section 409A to the maximum permissible
extent, and for any payments where such construction is not tenable, that those payments comply with Code Section 409A to the
maximum permissible extent. To the extent any payment under this letter agreement may be classified as a “short-term deferral”
within the meaning of Code Section 409A, such payment shall be deemed a short-term deferral, even if it may also qualify for an
exemption from Code Section 409A under another provision of Code Section 409A. Payments pursuant to this Offer Letter (or referenced
in this Offer Letter) are intended to constitute separate payments for purposes of Section 1.409A-2(b)(2) of the regulations under
Code Section 409A.
Required
I-9 Documentation.
Your employment with the Company is also subject to you providing, if you have not already done so, the
Company with proof of your legal right to work in the United States by completing the Form I-9 and providing Company with the
accepted documents specified on the Form I-9.
Certifications.
By
signing this letter, you certify to the Company that you are free to enter into and fully perform the duties of your position,
and that you are not subject to any employment, confidentiality, non-competition or other agreement that would restrict your performance
for the Company.
Additionally,
by signing this letter, you certify that you will not disclose to or use for the benefit of the Company any trade secret or confidential
or proprietary information of any previous employer. You further affirm that you have not divulged or used any such information
for the benefit of the Company, and that you have not and will not misappropriate any such information from any former employer.
Entire
Agreement
. This offer letter and your signed Business Protection Agreement, state the terms of your employment and supersede
and cancel any prior oral or written representations, offers or promises made by the Company and any understandings or agreements,
whether written or oral, between the Company and you.
|
Accepted by Employer:
|
|
Accepted by Employee:
|
|
|
|
|
|
/s/ William J. Febbo
|
|
/s/ Douglas P. Baker
|
|
William J. Febbo (Date)
|
|
Douglas P. Baker (Date)
|
Exhibit 10.3
Employment Agreement
This updated agreement made and entered into this June 27, 2016, by and
between OptimizeRx Corporation, a Nevada Company, hereinafter referred to as “Employer” and Terry Hamilton, hereinafter
referred to as the “Employee”.
The Employer is engaged in the business of Pharmaceutical and healthcare
promotion to physicians and consumers through their electronic platforms and other means and desires Terry Hamilton to serve as
the Senior Vice President of Sales for the company.
Base Compensation
. Your annual base salary is $181,650, payable
at a rate of $7,562.50 per semi-monthly pay period, representing payment for all hours worked (“Base Compensation”).
Your Base Compensation is payable in accordance with the Company’s regular practices.
Bonus.
In addition to your Base Compensation, you will be eligible
to participate in the Company’s executive bonus plan, subject to its terms and conditions, with an annual target bonus of
40 % of your Base Compensation. Subject to board approval and registration of the plans and related legal compliance, you will
have the option to take the bonus in equity or in a split 50/50 arrangement with 50% in cash and 50 % in equity. The option to
take all, or a portion, of your bonus in equity is at your discretion.
Employee Benefits.
In addition to your compensation, you will
have the opportunity to participate in various Company benefit programs generally offered to employees, pursuant to the terms and
conditions of such programs, including applicable waiting periods prior to eligibility. Currently, we offer employees a 401(k)
plan, group medical and dental insurance and short and long term disability benefits. Please note that the Company reserves the
right to change or discontinue any of our benefits, plans, providers, and policies, at any time.
Job Responsibilities
. As Sr. Vice President of Sales reporting
to the CEO, you are an essential member and part of our corporate management that is responsible for directing our sales force,
expanding our customer base, and achieving overall sales goals. You shall use your best efforts and devote your full time and attention
to the business of the Company on a full time basis and shall at all times faithfully and industriously and to the best of your
ability, experience and talent, perform all of the duties that may be required of you pursuant to the terms hereof. During the
term hereof you shall not engage in any other new employment or consulting activities without the express written consent of the
Company other than civic, charitable and/or religious activities, directing your own passive investments and/or serving on boards
of directors of other entities so long as such activities do not interfere or conflict with your duties hereunder as reasonably
determined by the Company.
Expense Reimbursement
. The Company will reimburse you for all approved
business travel costs incurred by you pursuant to the terms of the Company travel policy.
At-Will Employment.
Please note that you are not being offered
employment for a definite period of time, and that the Company may terminate your employment at any time for any reason, with or
without cause or notice, except as prohibited by law. Nothing in this offer to you should be interpreted as creating anything other
than an at-will employment relationship. You also have the right to terminate your employment with the company at any time for
any reason on thirty days’ prior written notice.
Business Protection Agreement.
The Company considers the protection
of its confidential information, proprietary materials and goodwill to be extremely important. Accordingly, as a condition of your
continued employment with the Company and the increase in bonus potential reflected herein, you will be required to execute and
return to the Company the enclosed Business Protection Agreement.
Conflicts of Interest and Gifts. You will promptly
disclose all current
and potential interests, direct or indirect, in any entity dealing with the Company which may affect actions and decisions made
by you as a representative of the Company, and fully disclose any gift which raises any reasonable possibility of conflict of interest.
Compliance
. You will comply with all applicable laws and Company
policies in performing your duties hereunder including federal and state securities laws.
Severance Pay
. If your employment agreement is terminated at any
time by the Company without cause, which termination shall be effective immediately upon the date of delivery of written notice
to you (or at such later date as otherwise specified in such notice), the Company shall continue to pay you, as severance pay,
the monthly portion of your Base Compensation for a period of twelve (12) months following such termination, subject to your continued
compliance with the terms and conditions of this Agreement and the Business Protection Agreement.
Except as set forth herein, or as set forth in your option agreements, or
as may be required by applicable law, you have no right to any specific compensation or benefits, and the Company shall have no
obligations to pay any salary, bonus, severance payment, accrued vacation or other amounts in connection with any termination of
your employment or attributable to the period after termination.
409A
. To the extent that any provision of this letter agreement is
ambiguous as to its exemption or compliance with Code Section 409A, the provision will be read in such a manner so that all payments
hereunder are exempt from Code Section 409A to the maximum permissible extent, and for any payments where such construction is
not tenable, that those payments comply with Code Section 409A to the maximum permissible extent. To the extent any payment under
this letter agreement may be classified as a “short-term deferral” within the meaning of Code Section 409A, such payment
shall be deemed a short-term deferral, even if it may also qualify for an exemption from Code Section 409A under another provision
of Code Section 409A. Payments pursuant to this Offer Letter (or referenced in this Offer Letter) are intended to constitute separate
payments for purposes of Section 1.409A-2(b)(2) of the regulations under Code Section 409A.
Required I-9 Documentation.
Your employment with the Company is also
subject to you providing, if you have not already done so, the Company with proof of your legal right to work in the United States
by completing the Form I-9 and providing Company with the accepted documents specified on the Form I-9.
Certifications.
By signing this letter, you certify to the Company
that you are free to enter into and fully perform the duties of your position, and that you are not subject to any employment,
confidentiality, non-competition or other agreement that would restrict your performance for the Company. .
Additionally, by signing this letter, you certify that you will not disclose
to or use for the benefit of the Company any trade secret or confidential or proprietary information of any previous employer.
You further affirm that you have not divulged or used any such information for the benefit of the Company, and that you have not
and will not misappropriate any such information from any former employer.
Entire Agreement
. This offer letter and your signed Business Protection
Agreement, state the terms of your employment and supersede and cancel any prior oral or written representations, offers or promises
made by the Company and any understandings or agreements, whether written or oral, between the Company and you.
|
Accepted by Employer:
|
|
Accepted by Employee:
|
|
|
|
|
|
/s/ William J. Febbo
|
|
/s/ Terry Hamilton
|
|
William J. Febbo (Date)
|
|
Terry Hamilton (Date)
|
Exhibit
99.1
OptimizeRx
Appoints Brian J. Dillon as SVP of Product and Strategy
ROCHESTER,
MI – June 22, 2016
–
OptimizeRx Corp. (OTCQB: OPRX), a health technology software company whose premier
content-delivery platform enables pharmaceutical companies to provide on-demand patient-care services, has appointed Brian J.
Dillon to the new position of SVP of Product and Strategy.
“Brian
brings over 25 years of experience serving companies in the healthcare and pharmaceutical industries, including a number of OptimizeRx’s
clients and channel partners,” said William Febbo, OptimizeRx’s CEO. “This appointment reflects our previously
announced growth initiative to build out our internal team to increase revenue and expand our reach within EHR providers and products.”
“He
will be responsible for strengthening our leadership position with our existing products, as well as launching additional products
and services for our pharmaceutical clients and channel partners,” continued Febbo. “His experience within health
technology and service companies makes him a great fit to help expand our EHR network and service offerings.”
Dillon
commented: “OptimizeRx provides very relevant and scalable solutions to the pharmaceutical industry. I’m looking forward
to working closely with management and OptimizeRx key partners, including WPP, Allscripts, Dr. First, among many others. These
partnerships indicate that we are very well positioned to scale our business, which we believe will help our expanding client
base to achieve better healthcare and outcomes for their patients.”
Febbo
added: “In the current quarter, we added two new team members to support our direct client outreach and channel partner
management. We believe these additional team members will drive growth with our existing solutions, as well as handle new products
and services that we plan to launch in 2016.”
Brian
J. Dillon Bio
Prior
to joining OptimizeRx, Dillon provided consulting services focused on the HiTECH (Health Information Technology) and pharmaceutical
manufacturers services sector. Earlier in his career, he served as partner at AccelaPartners, a consulting firm focused on Healthcare
technology and the pharmaceutical industry. Prior to AccelaPartners, he served as regional vice president of Americas at Cegedim,
an international healthcare software and services provider.
Dillon
was previously president and CEO of Intercon Systems. Before Intercon Systems, he was founder, president and CEO of Kelly Waldron,
which was eventually acquired by McKessonHBOC Technology Solutions, where he grew the company’s client base from one to
14 clients with over 5,000 individual users and grew the employee base from one to 75 employees in four years.
Earlier,
he served as vice president of sales at Walsh America, where he built the company’s client base from three to 13 companies
over three years with the company. Before Walsh America, he founded QuadROM Software Systems Inc. (North American division absorbed
into Walsh America), where he built a solid client base of more than 20 companies with over 10,000 users worldwide.
Dillon
currently serves as a director at Sofame Technologies Inc. and Visio Energy.
About
OptimizeRx Corp
OptimizeRx Corporation (OTCQB:OPRX) provides unique
consumer and physician platforms to help patients better afford and comply with their medicines and healthcare products, while
offering pharmaceutical and healthcare companies effective ways to expand awareness, access and adherence to their medications.
The
company’s core product, SampleMD, replaces drug samples with electronic trial vouchers and copay coupon savings that are
electronically added to an e-Prescription and sent electronically to the pharmacy and is integrated within leading electronic
health record (EHR) platforms in the country, including Allscripts, Quest Diagnostics, Practice Fusion and over 350 other EHRs
to reach over 250,000 healthcare providers. In turn, OptimizeRx promotes patient savings and support from the world’s largest
pharmaceutical companies, including Pfizer, Lilly, Novartis, AstraZeneca and many others. For more information, please go
to www.optimizerxcorp.com.
Important
Cautions Regarding Forward Looking Statements
This press release contains forward-looking statements
within the definition of Section 27A of the Securities Act of 1933, as amended and such section 21E of the Securities Act of 1934,
amended. These forward-looking statements should not be used to make an investment decision. The words 'estimate,' 'possible'
and 'seeking' and similar expressions identify forward-looking statements, which speak only as to the date the statement was made.
The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information,
future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot
be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by,
or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include,
but are not limited to, the effect of government regulation, competition and other material risks.
Company
Contact:
OptimizeRx
Doug Baker
dbaker@samplemd.com
248-651-6568 x807
Investor
Relations Contact:
Liolios Group
Ron Both, Senior Managing Director
oprx@liolios.com
949-574-3860